Global Information
회사소개 | 문의 | 위시리스트

세계의 저분자량 헤파린(LMWH) 시장 : 의약품 종류별(Enoxaparin, Dalteparin, Tinzaparin), 용도, 유통경로별 - 산업 인사이트, 동향, 전망, 기회 분석(2017-2025년)

Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, & Others), Application, & Distribution Channel - Global Industry Insights, Trends, Outlook, & Opportunity Analysis 2017-2025

리서치사 Coherent Market Insights
발행일 2019년 04월 상품 코드 833118
페이지 정보 영문
가격
US $ 4,500 ₩ 5,304,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,251,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,788,000 PPT Turned PDF (Enterprise User License)


세계의 저분자량 헤파린(LMWH) 시장 : 의약품 종류별(Enoxaparin, Dalteparin, Tinzaparin), 용도, 유통경로별 - 산업 인사이트, 동향, 전망, 기회 분석(2017-2025년) Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, & Others), Application, & Distribution Channel - Global Industry Insights, Trends, Outlook, & Opportunity Analysis 2017-2025
발행일 : 2019년 04월 페이지 정보 : 영문

저분자량 헤파린(LMWH : Low Molecular Weight Heparin)은 미분획 헤파린(UFH)에 비해 활성 기간이 길고 예측이 우수하며, 가정에서도 자기 피하 주사가 가능하고 정기적인 혈액검사를 필요로 하지 않습니다. 또한 헤파린은 태반을 통과하지 않고 태아에 대한 영향도 없으므로 혈전증 고위험 환자 및 임산부에게 응고제로서 이용되고 있습니다.

세계의 저분자량 헤파린 시장을 조사했으며, 시장 개요, 의약품·포장·용도·최종사용자·지역별 시장 규모의 추이와 예측, 시장 성장요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 개요

  • 리포트 개요
    • 시장의 정의와 범위
  • 개요
    • 시장 스니펫 : 의약품별
    • 시장 스니펫 : 포장별
    • 시장 스니펫 : 용도별
    • 시장 스니펫 : 최종사용자별
    • 시장 스니펫 : 지역별
  • COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장요인
    • 저해요인
    • 시장 기회
  • 영향 분석
  • 역학
  • 주요 개발 동향
  • 전략적 인수
  • LMWH의 이점 - 대 UFH비
  • LMWH와 UFH의 비용 효율
  • Enoxaparin 부족과 추정 보급일
  • 약물전달 시스템
  • 규제 시나리오
  • 상환 시나리오
  • PEST 분석

제4장 세계의 저분자량 헤파린 시장 : 의약품별

  • 서론
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • 기타

제5장 세계의 저분자량 헤파린 시장 : 포장별

  • 서론
  • 멀티 바이알
  • 프리필드 시린지

제6장 세계의 저분자량 헤파린 시장 : 용도별

  • 서론
  • 심부정맥혈전증
  • 급성관상동맥증후군(ACS)
  • 폐색전증
  • 심방세동

제7장 세계의 저분자량 헤파린 시장 : 최종사용자별

  • 서론
  • 병원
    • 공공병원
    • 민간병원
  • 진료소
  • 가정

제8장 세계의 저분자량 헤파린 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 프랑스
    • 스페인
    • 러시아
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • ASEAN
    • 호주
    • 한국
    • 기타
  • 중남미
    • 브라질
    • 멕시코
    • 아르헨티나
    • 기타
  • 아프리카
    • 북아프리카
    • 중앙아프리카
    • 남아프리카공화국
  • 중동
    • 걸프협력회의(GCC)
    • 이스라엘
    • 기타

제9장 경쟁 환경

  • 히트맵 분석
  • 기업 개요
    • Pfizer, Inc.
    • LEO Pharma A/S
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Amphastar Pharmaceuticals Inc.
    • Aspen Pharmacare Holdings
    • Laboratorios Farmaceuticos ROVI SA
    • Changzhou Qianhong Biopharma
    • Intrapharm Laboratories
    • Abbott Laboratories

제10장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights 소개
KSA 19.05.16

Low Molecular Weight Heparin (LMWH) has several advantages over other heparin such as longer and more predictable activity than Unfractionated Heparin (UFH) and can be self-administrated at home via subcutaneous injection, reducing or eliminating hospital stays, thereby no regular blood monitoring required. Furthermore, heparins do not cross the placenta or harm the fetus, so they are the preferred anticoagulants for pregnant women who experience or who are at heightened risk of - blood clots. These advantages make LMWH as the most preferred heparin in inhibiting clotting factors.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.

Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.

Key features of the study:

  • This report provides in-depth analysis of low molecular weight heparin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, low molecular weight heparin approval & launch, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global low molecular weight heparin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as part of this study include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, low molecular weight heparin based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the low molecular weight heparin market.

Detailed Segmentation:

  • Global Low Molecular Weight Heparin Market, By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
  • Global Low Molecular Weight Heparin Market, By Packaging:
  • Multi-vials
  • Prefilled Syringes
  • Global Low Molecular Weight Heparin Market, By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Global Low Molecular Weight Heparin Market, By End Use:
  • Hospitals
    • Private
    • Public
  • Clinics
  • Home
  • Global Low Molecular Weight Heparin Market, By Geography:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Europe
    • By Country:
  • Germany
  • France
  • Italy
  • UK
  • Spain
  • Russia
  • Rest of Europe
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Asia Pacific
    • By Country:
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Latin America
    • By Country:
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Africa
    • By Country:
  • South Africa
  • Central Africa
  • North Africa
    • By Drug:
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
    • By Packaging
  • Multi-vials
  • Prefilled Syringes
    • By Application:
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
    • By End Use:
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
  • Company Profiles
  • Pfizer, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments
    • Strategies
  • LEO Pharma A/S
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Abbott Laboratories
  • Aspen Pharmacare Holdings
  • Laboratorios Farmaceuticos ROVI SA
  • Changzhou Qianhong Biopharma
  • Intrapharm Laboratories

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Packaging
    • Market Snippet, By Application
    • Market Snippet, By End Use
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Key Developments
  • Strategic Acquisitions
  • Advantages of LMWH over UFH
  • Cost-effectiveness of LMWH vs. UFH
  • Shortage of Enoxaparin & Estimated Resupply Dates
  • Drug Delivery Systems
  • Regulatory Scenario
  • Reimbursement Scenario
  • Buy-and-bill and White Bagging Channel
  • PEST Analysis

4. Global Low Molecular Weight Heparin Market, By Drug, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Enoxaparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Dalteparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Nadroparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Bemiparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Tinzaparin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Low Molecular Weight Heparin Market, By Packaging, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Multi-vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Prefilled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Low Molecular Weight Heparin Market, By Application, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Deep Vein Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Acute Coronary Syndrome (ACS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Atrial Fibrillation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Low Molecular Weight Heparin Market, By End Use, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Home
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

8. Global Low Molecular Weight Heparin Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
  • North America
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
  • Middle East
    • Market Size and Forecast, By Drug, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Packaging, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By End Use, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Pfizer, Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • LEO Pharma A/S
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Sanofi S.A.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Amphastar Pharmaceuticals Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Aspen Pharmacare Holdings
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Laboratorios Farmaceuticos ROVI SA
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Changzhou Qianhong Biopharma
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Intrapharm Laboratories
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Abbott Laboratories
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top
전화 문의
F A Q